Antiemetic control and prevention of side effects of anti‐cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double‐blind, randomized trial

Cancer

Volumn 60, Issue 11, 1987, Pages 2816-2822

  Kris, Mark G ^a   Gralla, Richard J ^a   Clark, Rebecca A ^a   Tyson, Leslie B ^a   Groshen, Susan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; LORAZEPAM; METOCLOPRAMIDE;

ADVERSE DRUG REACTION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY; VOMITING;

ADULT; AGED; CISPLATIN; CLINICAL TRIALS; DEXAMETHASONE; DIPHENHYDRAMINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMAN; LORAZEPAM; MALE; MEMORY; METOCLOPRAMIDE; MIDDLE AGE; RANDOM ALLOCATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VOMITING;

EID: 0023230562     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7     Document Type: Article

References (39)

1. Cisplatin
2. Antiemetic efficacy of highdose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy‐induced nausea and vomiting
3. Metoclopramide as an antiemetic in patients receiving cisplatin
4. Double‐blind placebo‐controlled study of metoclopramide
5. Intravenous metoclopramide: An effective antiemetic in cancer chemotherapy
6. High dose metoclopramide as an antiemetic for patients receiving chemotherapy with cisplatinum
7. Antiemetic therapy: A review of recent studies and a report of a random assignment trial comparing metoclopramide with delta‐9‐tetrahydrocannabinol
8. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy
9. Double‐blind crossover study of the antiemetic efficacy of high‐dose dexamethasone versus high‐dose metoclopramide
10. Antiemetic efficacy of dexamethasone. Randomized double‐blind crossover study with prochloperazine in patients receiving cancer chemotherapy
11. Dexamethasone and high dose metoclopramide: Efficacy in controlling cisplatin induced nausea and vomiting
12. Improved control of cisplatin‐induced emesis with high‐dose metoclopramide and combinations of metoclopramide, dexamethasone and diphenhydramine: Results of consecutive trials in 255 patients
13. High‐dose intravenous metoclopramide versus combination high dose metoclopramide in preventing cisplatin‐induced nausea and emesis: A single‐blind crossover comparison of antiemetic efficacy
14. Comparison of metoclopramide (M) and metoclopramide + dexamethasone (M + D) in complete prevention of cisplatinum induced emesis
15. Antiemetic activity of high doses of metoclopramide (MTC) combined with methylprednisolone (P) vs. MTC alone in cisplatin treated cancer patients (PTS): A randomized double blind trial of the Italian Oncology Group for Clinical Research (GOIRC)
16. Extrapyramidal reactions with high‐dose metoclopramide
17. Metoclopramide: Dose‐related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy
18. Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions
19. Consecutive dose‐finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone
20. Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy
21. Improved tolerance of cytotoxic chemotherapy with lorazepam
22. Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy
23. A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for the prevention of chemotherapy‐induced vomiting
24. Phase I, II and III trials of a new antiemetic agent—lorazepam
25. Lorazepam: A randomized, double‐blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine
26. A pilot study of lorazepam‐induced amnesia with cis‐platinum containing chemotherapy
27. Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy
28. Lorazepam in cancer patients treated with cisplatin: A drug having antiemetic, amnestic and anxiolytic effects
29. Incidence, course, and severity of delayed nausea and vomiting following the administration of high‐dose cisplatin
30. Phase II evaluation of vindesine in patients with non‐small cell carcinoma of the lung
31. Vinblastine in neoplastic disease
32. Mitomycin: Ten years after approval for marketing
33. Correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER)
34. Antiemetic (AE) trials to control delayed vomiting (V) following high‐dose cisplatin
35. Sample size requirements for evaluating a conservative therapy
36. Phase I study of an extended regimen of oral metoclopramide (OM)
37. Management of cisplatin (DDP)‐induced delayed‐onset nausea (N) and vomiting (V): Preliminary results with 2 drug regimens
38. Double‐blind, randomized trial for the control of delayed emesis: Comparison of placebo vs. dexamethasone vs. metoclopramide plus dexamethasone